PGEN — Precigen, Inc.

Why people talked about PGEN (2026-11-02)

• Precigen shares dropped significantly following the FDA's accelerated approval of a rival treatment for RRP.
• The approval of Voceryq by Inovio caused a sharp decline in PGEN's stock price as it lost its competitive edge.
• Market activity was driven by the news that a competitor's product received regulatory clearance, impacting PGEN's valuation.